Abstract:We previously reported that acid-degradable methylated β-cyclodextrins (Me-β-CDs)-threaded polyrotaxanes (Me-PRXs) can induce autophagic cell death through endoplasmic reticulum (ER) stress-related autophagy, even in apoptosis-resistant cells. Hence, Me-PRXs show great potential as anticancer therapeutics. In this study, peptide-supermolecule conjugates were designed to achieve the targeted delivery of Me-PRX to malignant tumors. Arg-Gly-Asp peptides are well-known binding motifs of integrin αvβ3, which is overexpressed on angiogenic sites and many malignant tumors. The tumor-targeted cyclic Arg-Gly-Asp (cRGD) peptide was orthogonally post-modified to Me-PRX via click chemistry. Surface plasmon resonance (SPR) results indicated that cRGD-Me-PRX strongly binds to integrin αvβ3, whereas non-targeted cyclic Arg-Ala-Glu (cRGE) peptide conjugated to Me-PRX (cRGE-Me-PRX) failed to interact with integrins αvβ3. In vitro, cRGD-Me-PRX demonstrated enhanced cellular internalization and antitumor activity in 4T1 cells than that of unmodified Me-PRX and non-targeted cRGE-Me-PRX, due to its ability to recognize integrin αvβ3. Furthermore, cRGD-Me-PRX accumulated effectively in tumors, leading to antitumor effects, and exhibited excellent biocompatibility and safety in vivo. Therefore, cRGD conjugation to enhance selectivity for integrin αvβ3-positive cancer cells is a promising design strategy for Me-PRXs in antitumor therapy.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the targeting and anti - tumor activity of methylated β - cyclodextrin threaded polyrotaxanes (Me - PRXs) in tumor treatment. Specifically, the authors designed a complex capable of specifically recognizing integrin αvβ3 overexpressed on the surface of tumor cells by linking the cyclic arginine - glycine - aspartic acid (cRGD) peptide to Me - PRX. This design aims to overcome the shortcomings of traditional Me - PRXs, such as low endocytosis efficiency and lack of tumor - targeting ability, thereby enhancing their accumulation in tumor tissues and anti - tumor effects while avoiding toxicity to normal cells. ### Background of the paper - **Challenges in cancer treatment**: Traditional chemotherapeutic drugs mainly kill cancer cells by inducing apoptosis in cancer cells. However, the apoptotic mechanism is mutated in many malignant tumors, leading to the problem of multi - drug resistance. - **Autophagic cell death**: Autophagy is a non - apoptotic programmed cell death pathway that degrades unnecessary or dysfunctional cellular components through a lysosome - dependent mechanism. In recent years, inducing autophagic cell death has been considered as a potential strategy to overcome multi - drug resistance in cancer cells. - **Methylated β - cyclodextrin (Me - β - CD)**: Me - β - CD can form inclusion complexes with free cholesterol and induce autophagic cell death in cells, showing good anti - cancer potential. - **Polyrotaxanes (PRXs)**: Acid - degradable Me - PRXs can release Me - β - CD under acidic lysosomal conditions, and then induce endoplasmic reticulum stress - related autophagic cell death, but there are problems of low endocytosis efficiency and lack of tumor - targeting. ### Research purposes - **Improve the tumor - targeting of Me - PRXs**: By linking the cRGD peptide to Me - PRX, utilize the high affinity of the cRGD peptide for integrin αvβ3 to achieve the specific accumulation of Me - PRXs in tumor tissues. - **Enhance anti - tumor activity**: Verify the anti - tumor effects of cRGD - Me - PRX in vitro and in vivo, and evaluate its biocompatibility and safety. ### Main research contents 1. **Synthesis and characterization of cRGD - Me - PRX**: - Link the cRGD peptide to Me - PRX by click chemistry to prepare cRGD - Me - PRX. - Characterize cRGD - Me - PRX using nuclear magnetic resonance (NMR) and Fourier transform infrared spectroscopy (FT - IR) to confirm its successful synthesis. 2. **Cell experiments**: - Detect the binding ability of cRGD - Me - PRX to integrin αvβ3 by surface plasmon resonance (SPR) technology. - Evaluate the endocytosis efficiency and anti - tumor activity of cRGD - Me - PRX in 4T1 cells, and compare them with unmodified Me - PRX and non - targeted cRGE - Me - PRX. 3. **In vivo experiments**: - Evaluate the tumor accumulation and anti - tumor effects of cRGD - Me - PRX in 4T1 tumor - bearing mice by tail vein injection. - Detect the distribution of cRGD - Me - PRX in different tissues, and evaluate its biocompatibility and safety. ### Conclusions - **cRGD - Me - PRX has higher tumor - targeting and anti - tumor activity**: cRGD - Me - PRX can effectively recognize integrin αvβ3, enhance endocytosis efficiency, and significantly inhibit tumor growth. - **Good biocompatibility and safety**: cRGD - Me - PRX shows excellent biocompatibility and safety in vivo without obvious toxic side effects. Through these studies, the authors have demonstrated the great potential of cRGD - peptide - modified Me - PRXs in tumor - targeted therapy, providing new ideas for the development of new anti - cancer drugs.

Enhanced Tumor Targeting and Antitumor Activity of Methylated β-Cyclodextrin-Threaded Polyrotaxanes by Conjugating Cyclic RGD Peptides

RGD Peptide-Mediated Chitosan-Based Polymeric Micelles Targeting Delivery for Integrin-Overexpressing Tumor Cells.

RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells.

Dimeric camptothecin-loaded RGD-modified targeted cationic polypeptide-based micelles with high drug loading capacity and redox-responsive drug release capability.

Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature.

Novel RGD-decorated micelles loaded with doxorubicin for targeted breast cancer chemotherapy

Weakly acidic carboxy group-grafted β-cyclodextrin-threaded acid-degradable polyrotaxanes for modulating protein interaction and cellular internalization

Self-aggregated Pegylated Poly (trimethylene Carbonate) Nanoparticles Decorated with C(rgdyk) Peptide for Targeted Paclitaxel Delivery to Integrin-Rich Tumors

Synthesis And Biological Evaluation Of Rgd-Conjugated Mek1/2 Kinase Inhibitors For Integrin-Targeted Cancer Therapy

Molecular Basis For The Targeted Binding Of Rgd-Containing Peptide To Integrin Alpha(V)Beta(3)

Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Targeted Delivery of a Combination Therapy Consisting of Combretastatin A4 and Low-Dose Doxorubicin Against Tumor Neovasculature.

Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.

Scavenger Receptor A-Mediated Targeting of Carboxylated Polyrotaxanes to Macrophages and the Impacts of Supramolecular Structure

Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system

Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles

An Experimental Study On Targeted Therapy Of Radioiodinated Cyclic Crgd Peptide On Melanoma Bearing Mice

In Vivo Biodistribution and Anti-Tumor Efficacy Evaluation of Doxorubicin and Paclitaxel-Loaded Pluronic Micelles Decorated with c(RGDyK) Peptide

Deepened Cellular/subcellular Interface Penetration and Enhanced Antitumor Efficacy of Cyclic Peptidic Ligand-Decorated Accelerating Active Targeted Nanomedicines